Adjusted HRs for associations between the HCT-CI scores and risks of mortality following grades 2 and 3 to 4 acute GVHD among 2985 recipients of allogeneic HCT from 5 institutions
| HCT-CI scores . | Risk of mortality following grade 2 acute GVHD . | Risk of mortality following grades 3 to 4 acute GVHD . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| 0 | 1 | 1 | ||
| 1-2 | 1.67 (1.32-2.11) | <.0001 | 1.59 (1.15-2.20) | .006 |
| 3-4 | 2.52 (1.99-3.20) | <.0001 | 2.35 (1.68-3.27) | <.0001 |
| 5+ | 3.37 (2.48 −4.56) | <.0001 | 2.77 (1.90-4.05) | <.0001 |
| HCT-CI scores . | Risk of mortality following grade 2 acute GVHD . | Risk of mortality following grades 3 to 4 acute GVHD . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| 0 | 1 | 1 | ||
| 1-2 | 1.67 (1.32-2.11) | <.0001 | 1.59 (1.15-2.20) | .006 |
| 3-4 | 2.52 (1.99-3.20) | <.0001 | 2.35 (1.68-3.27) | <.0001 |
| 5+ | 3.37 (2.48 −4.56) | <.0001 | 2.77 (1.90-4.05) | <.0001 |
The models were adjusted for age, KPS, CMV serology results, donor/recipient gender combinations, diagnosis category, disease risk, number of prior regimens, donor type, stem-cell source, degree of conditioning intensity, inclusion of anti-thymocyte globulin in conditioning, and GVHD prophylaxis regimen.